[{"orgOrder":0,"company":"Dispatch Biotherapeutics","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Dispatch Biotherapeutics","amount2":0.22,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.22,"dosageForm":"Undisclosed","sponsorNew":"Dispatch Biotherapeutics \/ Arch Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Dispatch Biotherapeutics \/ Arch Ventures"}]

Find Clinical Drug Pipeline Developments & Deals by Dispatch Biotherapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AGGSpend
                          Not Confirmed
                          AGGSpend
                          Not Confirmed

                          Details : The proceeds from the financing will be used to advance the company’s therapeutic CAR‑T cell candidates into first-in-human clinical studies for the traetment of cancer.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 23, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Arch Ventures

                          Deal Size : $216.0 million

                          Deal Type : Series A Financing

                          blank